RxDoctor Payments Data

Rushik Bhuva, MD

Cardiovascular Disease · Orlando, FLNPI 1295113298

Payments from drug & device makers

$3,907in general payments, 2019–2025

Across 62 payments — averaging $63.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$731
  • Eisai Inc.$300
  • Heartflow, Inc.$244
  • Boston Scientific$221
  • Novo Nordisk$143
  • plus $717 from 14 others

What the payments were for

  • Travel & lodging$1,22331%
  • Food & beverage$2,61867%
  • Education$662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,907 in reported general payments places this provider in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$105,908
Medicare patients
453
Services billed
1,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$74,193
JardianceEmpagliflozin37$43,182
XareltoRivaroxaban16$18,583
Repatha SureclickEvolocumab11$13,327
Metoprolol Succinate94$1,246
Ezetimibe49$1,097
Atorvastatin Calcium75$684
Amlodipine Besylate60$613
Carvedilol50$560
Potassium Chloride16$499
Nifedipine ErNifedipine11$496
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$338
Spironolactone49$335
Furosemide76$321
Rosuvastatin Calcium32$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$74,19366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →